Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05166382 · ClinicalTrials.gov registry record · NA

Impact of SomaSignal Tests on the Choice of Glucose-lowering Medications

A NA study of Cardiovascular Diseases and Type 2 Diabetes, sponsored by University of Colorado, Denver.

Completed
Registry status
NA
Development phase
350
Enrollment target
1
Study location

NCT05166382 is a NA study of Cardiovascular Diseases and Type 2 Diabetes that has completed, run by University of Colorado, Denver. The registered enrollment target is 350 participants, below the 26,973-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05166382, a NA study of Cardiovascular Diseases and Type 2 Diabetes, has completed, sponsored by University of Colorado, Denver.

COMPLETED
Registry status
NA
Development phase
350 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to learn more about using a proteomic test called the SomaSignal Cardiovascular (CV) Risk Test in Type 2 Diabetes (CVD-T2D) to improve medical care for patients.

Interventions

  • BEHAVIORAL Informed of results from SomaSignal Cardiovascular Risk Test in Type 2 Diabetes (CVD-T2D)
  • BEHAVIORAL Not informed of results from SomaSignal Cardiovascular Risk Test in Type 2 Diabetes (CVD-T2D)

Study Locations (1)

Colorado

  • Aanchal Gupta - Aurora

Trial Details

FieldValue
Enrollment Target 350 participants
Start Date 2022-01-01
Est. Completion 2024-01-01
Phase NA

Sponsor

University of Colorado, Denver

1,283 total trials

What the Registry Record Tells You About NCT05166382

The ClinicalTrials.gov registry entry for NCT05166382 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 350 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 26,973-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (99% lower). The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Cardiovascular Diseases appearing as the primary indexed condition, and to 2 interventions - of which Informed of results from SomaSignal Cardiovascular Risk Test in Type 2 Diabetes (CVD-T2D) is the first listed.

NCT05166382 reports 1 study location spanning 1 distinct geographic area - top geographies include Colorado.

Frequently Asked Questions

What is clinical trial NCT05166382 about?

NCT05166382 is a clinical study titled "Impact of SomaSignal Tests on the Choice of Glucose-lowering Medications". The purpose of this study is to learn more about using a proteomic test called the SomaSignal Cardiovascular (CV) Risk Test in Type 2 Diabetes (CVD-T2D) to improve medical care for patients.

What is the current status of trial NCT05166382?

This trial is currently completed. It is a NA study. The enrollment target is 350 participants. The study started on 2022-01-01. Estimated completion is 2024-01-01.

What conditions does trial NCT05166382 study?

This clinical trial studies the following conditions: Cardiovascular Diseases, Type 2 Diabetes.

What interventions are being tested in trial NCT05166382?

The interventions under investigation include: Informed of results from SomaSignal Cardiovascular Risk Test in Type 2 Diabetes (CVD-T2D) (BEHAVIORAL), Not informed of results from SomaSignal Cardiovascular Risk Test in Type 2 Diabetes (CVD-T2D) (BEHAVIORAL).

Who is sponsoring clinical trial NCT05166382?

This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05166382 being conducted?

This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cardiovascular Diseases

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.